Mobile

An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabe...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005431-97

An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women with Overactive Bladder

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare the efficacy of solabegron 125mg and 50mg administered twice daily, to that of placebo in female subjects with OAB including symptoms of urgency with urge incontinence and frequency which may be associated with nocturia, but without bladder related pain.

Critère d'inclusion

  • Overactive bladder (OAB)

Liens